Skip to main content
C

Celestra Inc. — Investor Relations & Filings

Ticker · 352770 ISIN · KR7352770002 KO Telecommunications, computer programming, consultancy, computing infrastructure, and other information service activities
Open in API
Filings indexed 378 across all filing types
Latest filing 2022-04-27 Director's Dealing
Country KR South Korea
Listing KO 352770

About Celestra Inc.

https://celestrahealth.com/

Celestra Inc. develops and commercializes digital biomarkers for monitoring neurological conditions. The company's core product is the Celestra Health platform, an FDA-designated Class II medical device that provides quantitative gait analysis for patients in their natural environment. The platform utilizes wearable smart insoles equipped with gyroscopes, accelerometers, and pressure sensors to collect movement data. This data is processed by a cloud-based system using advanced machine learning algorithms to measure over 200 aspects of a patient's gait. The system is designed to detect subtle changes in disease progression for conditions such as Multiple Sclerosis and Parkinson’s Disease earlier than traditional clinical assessments. It offers laboratory-grade accuracy, providing clinicians with actionable insights through a proprietary composite index and enabling pharmaceutical firms to assess drug therapy effectiveness more efficiently.

Recent filings

Filing Released Lang Actions
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 1% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). It details the share ownership and changes in holdings (specifically stock option exercises) by an executive (Ko Yu-seok) of Clinomics. This type of filing is a standard regulatory requirement for insider trading and ownership reporting, which corresponds to the 'Director's Dealing' category.
2022-04-27 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 1% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). It details the share ownership and changes in holdings (specifically stock option exercises) by a company executive (Jeong Myeong-jun) of Clinomics. This type of filing is a standard regulatory requirement for insider trading and ownership reporting, which corresponds to the 'Director's Dealing' category.
2022-04-27 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 1% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). This is a standard regulatory filing in South Korea (DART system) used by insiders (directors/executives) to report their personal share transactions or changes in ownership. This corresponds to the 'Director's Dealing' category.
2022-04-27 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 1% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details changes in share ownership by major shareholders and special related parties, including specific transaction dates, methods (market purchase, stock option exercise), and updated shareholding percentages. This fits the definition of a Major Shareholding Notification (MRQ).
2022-04-27 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is an official announcement of the results of a General Meeting of Shareholders (AGM). It explicitly lists the agenda items (financial statement approval, board remuneration, etc.) and the outcome of the votes for each item (e.g., '원안대로 승인됨' - approved as proposed). This fits the definition of a Declaration of Voting Results & Voting Rights Announcement (DVA).
2022-03-28 Korean
대표이사변경
Board/Management Information Classification · 1% confidence The document is a formal announcement regarding a change in the company's CEO (대표이사변경). It details the transition from joint CEOs to separate CEOs, the effective date, and the board resolution date. This falls directly under the category of board/management changes.
2022-03-28 Korean

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.